The Estée Lauder Companies Announces Cedric Prouvé, Group President, International, to Retire After Exceptional Career
26.10.2021 14:15:00 EEST | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) (“ELC”) announced that after 27 years with the company, Cedric Prouvé, Group President, International, has made the decision to retire effective June 30, 2022. The successor to Cedric’s role will be announced shortly, and Cedric will partner with this individual starting in February 2022 to support a smooth and successful transition.
A visionary and highly-respected global leader, Cedric has, alongside his outstanding global teams, led ELC’s winning international business – including all sales and profits outside of North America, all activities of sales affiliates and distributor relationships worldwide, as well as the Travel Retail business – since 2003. Throughout his exceptional career, Cedric has been instrumental in elevating and operationalizing the company’s global network of Region Presidents and Affiliate General Managers, and has collaborated closely with Group and Brand Presidents and Function Leaders to integrate global marketing strategies in international markets.
Under Cedric’s leadership, ELC’s international business has grown significantly since 2003 – from approximately 43% of the business to approximately 77% of the business in fiscal year 2021. During his tenure, the company’s international organization has expanded to over 35 affiliates doing business in 150+ countries and territories across our international footprint, with strategic investments in talent, third-party relationships, and innovation pipelines in established and emerging markets.
“In a rapidly-changing industry, Cedric’s strategic vision, inspiring leadership style and unique team-building abilities have been integral to the success of ELC’s International business, and we are well-positioned for future growth,” said Fabrizio Freda, President and Chief Executive Officer. “I have greatly enjoyed my close partnership with Cedric over the years, and I would like to thank him for leading our International organization with a great blend of enthusiasm, thoughtfulness, and most especially, kindness. His positive energy, dynamic style, caring nature and deep international expertise will be truly missed.”
Among Cedric’s many accomplishments, he played a key role in establishing the company’s International structure, helping to develop and implement ELC’s successful regional and affiliate framework. Within that structure, he has built a diverse team of outstanding global and local experts, nurturing deep and lasting relationships with Region Presidents and Affiliate General Managers around the world, and fostering close ties with key global retailers and commercial partners.
During his tenure, Cedric sponsored many enterprise-wide initiatives and strategic transformational priorities to help ensure the company is building the right capabilities in the Asia/Pacific (APAC) Region and in China, its second home market. From the earliest days of this strategic work, Cedric helped to shape the value chain proposition that ultimately resulted in the implementation of ELC’s new Shanghai Innovation Center and its Japan-based manufacturing facility, both of which will be instrumental in continuing to position the company for long-term growth in the region and globally.
Since joining ELC in 1994, Cedric’s career trajectory has included leadership roles spanning regions, affiliates and business areas. He joined the company as General Manager (GM) for Travel Retail in the APAC Region, and soon thereafter added the responsibility of GM for the Singapore affiliate. He also served as Vice President, GM, Travel Retail Worldwide, navigating a wide range of challenges while proactively managing opportunities arising from the introduction of new brands and specialized marketing programs for the Travel Retail channel. Prior to his promotion to Group President, International, Cedric was the President and GM of the Japan affiliate.
“Throughout his career, Cedric’s keen ability to lead with our company values and foster meaningful partnerships across the enterprise has led to significant contributions across the business, while also enriching our company’s culture,” said William P. Lauder, Executive Chairman. “We have all benefitted from Cedric’s strategic insights and his candid and charismatic communication style. On behalf of the company and the Lauder family, I would like to wish Cedric the very best in his well-deserved retirement.”
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005441/en/
Contact information
Investors: Rainey Mancini
rmancini@estee.com
Media: Jill Marvin
jimarvin@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
